BCBS drops US antitrust claims against Celgene over Revlimid, Thalomid
MLex Summary: Blue Cross Blue Shield agreed to voluntarily dismiss without prejudice US claims accusing Celgene of engaging in an overarching, multi-pronged course of conduct to unlawfully exercise monopoly power in...To view the full article, register now.
Already a subscriber? Click here to view full article